secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001213900-25-084737
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for CER-1236 in AML, adding to existing Orphan Drug Designation.
- Benefits include increased FDA interactions, potential priority review, rolling submission, and expanded access.
- Phase 1/1b study underway evaluating CER-1236 in relapsed/refractory AML, MRD-positive, or TP53-mutated MDS/AML.
- CEO Chris Ehrlich noted the designation validates program urgency and may accelerate development and market timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025084737/0001213900-25-084737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025084737/ea0256155-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-084737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer